P-1064. Beta-Lactams Strike Back: Challenging Resistance Assumptions in Serratia marcescens

Abstract Background The management of serious Serratia marcescens (SEM) infections is controversial due to the uncertainty of clinically significant ampC beta-lactamase overexpression. The purpose of this study was to evaluate differences in clinical outcomes in patients with SEM bloodstream infection (BSI) or pneumonia (PNA) who receive ceftriaxone (CRO), piperacillin-tazobactam (TZP), or cefepime (FEP).Table 1.Patient demographics and clinical characteristics of SEM managementTable 2.Effect Modification of the Primary and Secondary Outcomes Comparing Individual Beta-Lactams Methods This IRB-approved retrospective, multi-center cohort study included adult patients hospitalized with SEM BSI or PNA over a 10-year period at UF Health. Based on the definitive antibiotic regimen, patients were assigned to CRO, TZP or FEP groups. The primary composite endpoint was treatment failure: persistent infection (fever or leukocytosis on day five of antibiotics), recurrent infection, or microbiological relapse. Secondary outcomes included hospital length of stay (LOS) and escalation of therapy. Results A total of 291 patients were included in the study and stratified by definitive antibiotic regimen: CRO (n=45), TZP (n=55), and FEP (n=191). Treatment failure did not differ significantly between CRO (48.9%), TZP (50.9%), and FEP (52.4%), p=0.911. There was no difference in median LOS, with 25.2 days (IQR: 11.2 - 37.1) in the CRO group, 14 days (IQR: 7.1-34.1) in the TZP group, and 17.5 days (IQR: 8.8 - 29.8) in the FEP group, p=0.784. A significantly higher proportion of patients in the CRO (20%) and TZP (32.7%) groups required escalation of therapy compared to FEP (7.3%), p< 0.001. Conclusion Treatment with CRO or TZP was not associated with increased treatment failure rates in adult patients being treated for SEM BSI or PNA, but were associated with increased incidence of antibiotic escalation. Disclosures All Authors: No reported disclosures

Authors

Institutions

Publication Details

Journal
Open Forum Infectious Diseases
Published
2026-01-01
DOI
https://doi.org/10.1093/ofid/ofaf695.1259
Primary Topic
Antibiotic Resistance in Bacteria
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P-1064. Beta-Lactams Strike Back: Challenging Resistance Assumptions in Serratia marcescens

Yvette S. McCarter, Carmen Isache, Christopher Jankowski, Anthony M. Casapao et al.
Open Forum Infectious Diseases
Antibiotic Resistance in Bacteria
article

P-1064. Beta-Lactams Strike Back: Challenging Resistance Assumptions in Serratia marcescens

Yvette S. McCarter, Carmen Isache, Christopher Jankowski, Anthony M. Casapao, Lisa Vuong, Caroline L Terrell, Makayla A Bresnock, Danielle K Sanchez
article en

Abstract

Abstract Background The management of serious Serratia marcescens (SEM) infections is controversial due to the uncertainty of clinically significant ampC beta-lactamase overexpression. The purpose of this study was to evaluate differences in clinical outcomes in patients with SEM bloodstream infection (BSI) or pneumonia (PNA) who receive ceftriaxone (CRO), piperacillin-tazobactam (TZP), or cefepime (FEP).Table 1.Patient demographics and clinical characteristics of SEM managementTable 2.Effect Modification of the Primary and Secondary Outcomes Comparing Individual Beta-Lactams Methods This IRB-approved retrospective, multi-center cohort study included adult patients hospitalized with SEM BSI or PNA over a 10-year period at UF Health. Based on the definitive antibiotic regimen, patients were assigned to CRO, TZP or FEP groups. The primary composite endpoint was treatment failure: persistent infection (fever or leukocytosis on day five of antibiotics), recurrent infection, or microbiological relapse. Secondary outcomes included hospital length of stay (LOS) and escalation of therapy. Results A total of 291 patients were included in the study and stratified by definitive antibiotic regimen: CRO (n=45), TZP (n=55), and FEP (n=191). Treatment failure did not differ significantly between CRO (48.9%), TZP (50.9%), and FEP (52.4%), p=0.911. There was no difference in median LOS, with 25.2 days (IQR: 11.2 - 37.1) in the CRO group, 14 days (IQR: 7.1-34.1) in the TZP group, and 17.5 days (IQR: 8.8 - 29.8) in the FEP group, p=0.784. A significantly higher proportion of patients in the CRO (20%) and TZP (32.7%) groups required escalation of therapy compared to FEP (7.3%), p< 0.001. Conclusion Treatment with CRO or TZP was not associated with increased treatment failure rates in adult patients being treated for SEM BSI or PNA, but were associated with increased incidence of antibiotic escalation. Disclosures All Authors: No reported disclosures

Open Forum Infectious DiseasesVol. 13(Supplement_1)
University of Florida Health (US), University of Florida (US), Jacksonville University (US), University of Florida Health Science Center (US), Florida College (US)
Good health and well-being
Openalex Percentile: Top 89%
Antibiotic Resistance in Bacteria
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.